JP7679300B2 - ＤｃＲ３改変体 - Google Patents

ＤｃＲ３改変体 Download PDF

Info

Publication number
JP7679300B2
JP7679300B2 JP2021545613A JP2021545613A JP7679300B2 JP 7679300 B2 JP7679300 B2 JP 7679300B2 JP 2021545613 A JP2021545613 A JP 2021545613A JP 2021545613 A JP2021545613 A JP 2021545613A JP 7679300 B2 JP7679300 B2 JP 7679300B2
Authority
JP
Japan
Prior art keywords
amino acid
dcr3
acid sequence
seq
variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021545613A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021049606A1 (https=
JPWO2021049606A5 (https=
Inventor
暁子 金井
仁美 細見
早紀子 米澤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Co Ltd
Original Assignee
Kyowa Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Kirin Co Ltd filed Critical Kyowa Kirin Co Ltd
Publication of JPWO2021049606A1 publication Critical patent/JPWO2021049606A1/ja
Publication of JPWO2021049606A5 publication Critical patent/JPWO2021049606A5/ja
Priority to JP2025077324A priority Critical patent/JP2025121978A/ja
Application granted granted Critical
Publication of JP7679300B2 publication Critical patent/JP7679300B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021545613A 2019-09-13 2020-09-11 ＤｃＲ３改変体 Active JP7679300B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025077324A JP2025121978A (ja) 2019-09-13 2025-05-07 ＤｃＲ３改変体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019167728 2019-09-13
JP2019167728 2019-09-13
PCT/JP2020/034444 WO2021049606A1 (ja) 2019-09-13 2020-09-11 ＤｃＲ３改変体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025077324A Division JP2025121978A (ja) 2019-09-13 2025-05-07 ＤｃＲ３改変体

Publications (3)

Publication Number Publication Date
JPWO2021049606A1 JPWO2021049606A1 (https=) 2021-03-18
JPWO2021049606A5 JPWO2021049606A5 (https=) 2023-09-19
JP7679300B2 true JP7679300B2 (ja) 2025-05-19

Family

ID=74865719

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545613A Active JP7679300B2 (ja) 2019-09-13 2020-09-11 ＤｃＲ３改変体
JP2025077324A Pending JP2025121978A (ja) 2019-09-13 2025-05-07 ＤｃＲ３改変体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025077324A Pending JP2025121978A (ja) 2019-09-13 2025-05-07 ＤｃＲ３改変体

Country Status (10)

Country Link
US (1) US20220340642A1 (https=)
EP (1) EP4056232B1 (https=)
JP (2) JP7679300B2 (https=)
KR (1) KR20220061967A (https=)
CN (3) CN121930331A (https=)
AU (1) AU2020346580A1 (https=)
BR (1) BR112022004590A2 (https=)
CA (1) CA3154191A1 (https=)
TW (1) TW202124425A (https=)
WO (1) WO2021049606A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7749319B2 (ja) 2017-10-10 2025-10-06 アルパイン イミューン サイエンシズ インコーポレイテッド Ｃｔｌａ－４変異型免疫調節タンパク質およびそれらの使用
US20230159649A1 (en) * 2020-04-02 2023-05-25 La Jolla Institute For Immunology Methods and combinations for dual targeting of tnf family members
EP4146684A2 (en) 2020-05-08 2023-03-15 Alpine Immune Sciences, Inc. April and baff inhibitory immunomodulatory proteins with and without a t cell inhibitory protein and methods of use thereof
EP4370545A1 (en) * 2021-07-12 2024-05-22 Genentech, Inc. Structures for reducing antibody-lipase binding
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法
TW202545974A (zh) * 2024-01-26 2025-12-01 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 免疫受體抑制蛋白及相關方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001516581A (ja) 1997-09-18 2001-10-02 ジェネンテク・インコーポレイテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT311902B (de) 1970-04-29 1973-10-15 Herrmann W Ionenaustauschfilter,insbesondere kleinfilter
ZA872705B (en) 1986-04-22 1987-10-05 Immunex Corporation Human g-csf protein expression
JP2928287B2 (ja) 1988-09-29 1999-08-03 協和醗酵工業株式会社 新規ポリペプチド
JPH02257891A (ja) 1989-03-31 1990-10-18 Kyowa Hakko Kogyo Co Ltd 組換え動物細胞による蛋白質の製造
JPH0322979A (ja) 1989-06-19 1991-01-31 Kyowa Hakko Kogyo Co Ltd 新規プラスミノーゲン活性化因子
ES2233974T3 (es) 1995-09-11 2005-06-16 Kyowa Hakko Kogyo Co., Ltd. Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana.
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
US6965012B1 (en) 1999-03-30 2005-11-15 Eli Lilly And Company Flint polypeptide analogs
US6835814B1 (en) 1999-03-30 2004-12-28 Eli Lilly And Company Protease resistant flint analogs
CA2953239A1 (en) 2000-10-06 2002-04-18 Kyowa Hakko Kirin Co., Ltd. Antibody composition-producing cell
JPWO2005035586A1 (ja) 2003-10-08 2007-11-22 協和醗酵工業株式会社 融合蛋白質組成物
EP1810979B1 (en) 2004-09-22 2012-06-20 Kyowa Hakko Kirin Co., Ltd. STABILIZED HUMAN IgG4 ANTIBODIES
BRPI0519008A2 (pt) * 2004-12-13 2008-12-23 Evogenix Ltd proteÍnas variantes de osteoprotegerina
AU2007290570C1 (en) 2006-08-28 2013-08-15 Kyowa Kirin Co., Ltd. Antagonistic human LIGHT-specific human monoclonal antibodies
EP2653540B9 (en) 2010-12-15 2018-05-16 Inter-University Research Institute Corporation Research Organization of Information and Systems Protein production method
US20140193410A1 (en) * 2013-01-09 2014-07-10 University Of Miami Compositions and Methods for the Regulation of T Regulatory Cells Using TL1A-Ig Fusion Protein
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
ES2894963T3 (es) * 2013-05-17 2022-02-16 Cedars Sinai Medical Center Variantes de TNFSF15 y DcR3 asociadas con la enfermedad de Crohn
US9683998B2 (en) 2013-11-13 2017-06-20 Pfizer Inc. Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof
EP3730188B1 (en) * 2015-08-21 2024-07-31 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001516581A (ja) 1997-09-18 2001-10-02 ジェネンテク・インコーポレイテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体

Also Published As

Publication number Publication date
TW202124425A (zh) 2021-07-01
BR112022004590A2 (pt) 2022-06-14
CN114450301A (zh) 2022-05-06
CN114450301B (zh) 2025-12-05
KR20220061967A (ko) 2022-05-13
US20220340642A1 (en) 2022-10-27
WO2021049606A1 (ja) 2021-03-18
AU2020346580A1 (en) 2022-03-31
EP4056232A4 (en) 2023-09-13
JPWO2021049606A1 (https=) 2021-03-18
EP4056232B1 (en) 2026-05-06
EP4056232A1 (en) 2022-09-14
CN121930331A (zh) 2026-04-28
JP2025121978A (ja) 2025-08-20
CA3154191A1 (en) 2021-03-18
CN121949515A (zh) 2026-05-01

Similar Documents

Publication Publication Date Title
JP7679300B2 (ja) ＤｃＲ３改変体
US12466886B2 (en) Method of treatment using a bispecific antibody binding bcma and CD3
KR102884523B1 (ko) IL-12 이종이량체 Fc-융합 단백질
EP3504242B1 (en) Anti-ox40 antibodies and their uses
JP7746258B2 (ja) 特性が改善されたｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒαｆｃ融合タンパク質
US8669350B2 (en) TNF receptor Fc fusion proteins and in vivo methods of use
RU2722829C9 (ru) Антигенсвязывающая молекула, индуцирующая иммунный ответ на антиген-мишень
KR20230029622A (ko) April 및 baff 억제 면역조절 단백질 및 사용 방법
KR20190014525A (ko) 면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
TW201726745A (zh) 促進抗原消失的抗原結合分子
CN115925950A (zh) 新型抗ifnar1抗体
JP7529568B2 (ja) 抗体組成物
JP7744330B2 (ja) 抗体組成物
WO2025144089A1 (en) Monoclonal antibody that specifically binds to tl1a
JP7833531B2 (ja) Ｃｄ４０を特異的に認識する抗体およびその使用
CN121532432A (zh) 免疫治疗蛋白
HK40067776A (en) Dcr3 variant
WO2025242836A1 (en) Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
RU2799423C1 (ru) Способ изменения удержания в плазме и иммуногенности антигенсвязывающей молекулы
HK40052031A (en) Bispecific antibody and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220422

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230908

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230908

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240221

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241001

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250219

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250507

R150 Certificate of patent or registration of utility model

Ref document number: 7679300

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150